Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) in Elderly (More Than 60 Years) Patients With Diffuse Large B Cell Lymphoma After 4 Cycles of CHOP21-Rituximab (CHOP21-R) Therapy [Phase 2]

View source ↗

Summary

A Phase 2 study assessing the efficacy and safety of Zevalin (ibritumomab tiuxetan) as subsequent therapy in elderly patients with Diffuse Large B-Cell Lymphoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Zevalin (ibritumomab tiuxetan)

Snippet

Sponsor: University of Bologna | Conditions: Diffuse Large B-Cell Lymphoma | Phase 2 | Status: COMPLETED